| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Preeclampsia sFlt-1/PlGF Ratio, Serum
MessageSendouts, Mayo test code: PERA
Test Code
LAB1238554
Alias/See Also
Preeclampsia
SFLT
PLGF
SFLT/PLGF Ratio
Preeclampsia sFlt-1/PIGF (Soluble fms-Like Tyrosine Kinase 1/ Placental Growth Factor) Ratio, Serum
SFLT
PLGF
SFLT/PLGF Ratio
Preeclampsia sFlt-1/PIGF (Soluble fms-Like Tyrosine Kinase 1/ Placental Growth Factor) Ratio, Serum
CPT Codes
0482U
Preferred Specimen
0.5 mL serum from a serum gel tube.
Patient Preparation
For 24 hours before specimen collection, the patient should not receive intravenous heparin.
Minimum Volume
0.3 mL
Other Acceptable Specimens
Red tube
Transport Container
Plastic vial
Transport Temperature
Frozen
Specimen Stability
Frozen: 180 days
Refrigerated: 24 hours
Refrigerated: 24 hours
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis OK
Gross lipemia OK
Gross icterus Reject
Gross lipemia OK
Gross icterus Reject
Methodology
Immunofluorescent Assay (IFA)
Setup Schedule
Monday through Saturday
Report Available
1 to 3 days
Limitations
The B·R·A·H·M·S PIGF (placental growth factor) plus KRYPTOR assay must be run in conjunction with the B·R·A·H·M·S sFlt-1 (soluble fms-like tyrosine kinase 1) KRYPTOR assay and the same patient sample must be used to run both assays. Use of another manufacturer's assays may result in significantly different results.
The sFlt-1/PlGF ratio should not be used for a woman with a multiple pregnancy because the safety and effectiveness of the assay has not been established in women pregnant with multiple fetuses (twins, triplets, etc).
The sFlt-1/PlGF ratio should not be used for a woman receiving intravenous heparin for 24 hours prior to testing because the safety and effectiveness of the assay has not been established in such cases.
The sFlt-1/PlGF ratio should not be used for women receiving exogenous PlGF-2 or PlGF-3 for therapeutic use at concentrations higher than 100 pg/mL because the safety and effectiveness of the assay has not been established in such cases. However, in samples with equal concentrations of PIGF-1 and PIGF-2, the measurement of PIGF-1 was relatively unaffected.
The results of the test are not intended to inform the healthcare provider whether to change treatment, including medication or hospitalization.
In rare cases, some individuals can develop antibodies to mouse or other animal antibodies (often referred to as human anti-mouse antibodies [HAMA] or heterophile antibodies), which may cause interference in some immunoassays. Caution should be used in interpretation of results, and the laboratory should be alerted if the result does not correlate with the clinical presentation.
The sFlt-1/PlGF ratio should not be used for a woman with a multiple pregnancy because the safety and effectiveness of the assay has not been established in women pregnant with multiple fetuses (twins, triplets, etc).
The sFlt-1/PlGF ratio should not be used for a woman receiving intravenous heparin for 24 hours prior to testing because the safety and effectiveness of the assay has not been established in such cases.
The sFlt-1/PlGF ratio should not be used for women receiving exogenous PlGF-2 or PlGF-3 for therapeutic use at concentrations higher than 100 pg/mL because the safety and effectiveness of the assay has not been established in such cases. However, in samples with equal concentrations of PIGF-1 and PIGF-2, the measurement of PIGF-1 was relatively unaffected.
The results of the test are not intended to inform the healthcare provider whether to change treatment, including medication or hospitalization.
In rare cases, some individuals can develop antibodies to mouse or other animal antibodies (often referred to as human anti-mouse antibodies [HAMA] or heterophile antibodies), which may cause interference in some immunoassays. Caution should be used in interpretation of results, and the laboratory should be alerted if the result does not correlate with the clinical presentation.
Reference Range
Included with report
Clinical Significance
Aiding in risk assessment of patients with clinical signs and symptoms consistent with development of preeclampsia with severe features
This test is not intended for making a diagnosis of preeclampsia or preeclampsia with severe features.
This test is not a stand-alone test for monitoring of hypertensive disorders of pregnancy or for changing treatment, including medication.
This test is not intended for making a diagnosis of preeclampsia or preeclampsia with severe features.
This test is not a stand-alone test for monitoring of hypertensive disorders of pregnancy or for changing treatment, including medication.
Performing Laboratory
Mayo Clinic Laboratories, Rochester, Minnesota
Additional Information
Preeclampsia sFlt-1/PlGF Ratio, Serum
